Psychiatric comorbidities in patients with Parkinson disease and psychosis

Neurology

Volumn 63, Issue 2, 2004, Pages 293-300

  Marsh, Laura ^a   Williams, J R ^a   Rocco, M ^a   Grill, S ^a   Munro, C ^a   Dawson, T M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; BENZODIAZEPINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; HYPNOTIC SEDATIVE AGENT; LEVODOPA; NEUROLEPTIC AGENT; SELEGILINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CAREGIVER; COMORBIDITY; DAILY LIFE ACTIVITY; DELIRIUM; DELUSION; DEPRESSION; FEMALE; FUNCTIONAL ASSESSMENT; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROLOGIC DISEASE; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; SCORING SYSTEM; SYMPTOMATOLOGY;

EID: 3242744394     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000129843.15756.A3     Document Type: Article

References (46)

1. Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson's disease. Prevalence, phenomenology, and risk factors. Brain 2000;123:733-745.
2. Aarsland D, Larsen JP, Cummings JL, Laake K, Prevalence and clinical correlates of psychotic symptoms in Parkinson disease. A community-based study. Arch Neurol 1999;56:595-601.
3. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;70:734-738.
4. Aarsland D, Larsen JP, Karlsen K, et al. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999;14:866-874.
5. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-2229.
6. Factor S, Feustel PJ, Friedman J, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003;60:1756-1761.
7. Giladi N, Treves TA, Paleacu D, et al. Risk factors for dementia, depression, and psychosis in long-standing Parkinson's disease. J Neural Transm 2000;107:59-71.
8. Tandberg E, Larsen JP, Aarsland D, Laake K, Cummings JL. Risk factors for depression in Parkinson's disease. Arch Neurol 1997;54:625-630.
9. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
10. McKeith IG, Ballard CG, Perry RH, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000;54:1050-1058.
11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
12. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition. New York: 1995.
13. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
14. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
15. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997;48(suppl 6):10-16.
16. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, eds. Recent developments in Parkinson's disease II. New York: Macmillan, 1987;153-163.
17. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
18. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
19. Mattis S. Dementia Rating Scale (DRS) professional manual. Odessa, FL: Psychological Assessment Resources, 1988.
20. Blair JR, Spreen O. Predicting premorbid IQ: a revision of the National Adult Reading Test. Clin Neuropsychol 1989;3:129-136.
21. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feeling of burden. Gerontologist 1980;20:649-655.
22. Romito LMA, Scerrati M, Contarino MF, Bentivoglio AR, Tonali P, Albanese A. Long-term follow up of subthalamic stimulation in Parkinson's disease. Neurology 2002;58:1546-1550.
23. Levy G, Tang M-X, Cote LJ, et al. Motor impairment in PD. Relationship to incident dementia and age. Neurology 2000;55:539-544.
24. Birkmayer W, Riederer P. Responsibility of extrastriatal areas for the appearance of psychotic symptoms. J Neural Transm 1975;37:175-182.
25. Goodwin FK. Psychiatric side effects of levodopa in man. JAMA 1971;218:1915-1920.
26. Graham JM, Grunewald RA, Sagar HJ. Hallucinations in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:434-440.
27. Barnes J, David AS. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 2001;70:727-733.
28. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996;53:1265-1268.
29. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:533-535.
30. Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978;135:669-675.
31. Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol 1997;244:2-8.
32. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sørensen P. Risk of dementia in Parkinson's disease. A community-based prospective study. Neurology 2001;56:730-736.
33. Woods SP, Tröster AI. Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease. J Int Neuropsychol Soc 2003;9:17-24.
34. Goetz CG, Pappert EJ, Blasucci LM. Intravenous levodopa in chronically-treated hallucinating Parkinson's patients: high dose pharmacological challenge does not precipitate visual hallucinations. Neurology 1998;50:515-517.
35. Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson's disease. Neurology 1984;34:1092-1094.
36. Lauterbach EC. Dopaminergic hallucinosis with fluoxetine in Parkinson's disease. Am J Psychiatry 1993;150:1750.
37. Juncos JL. Management of psychotic aspects of Parkinson's disease. J Clin Psychiatry 1999;60:42-53.
38. Zoldan J, Friedberg G, Weizman A, Melamed E. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. Adv Neurol 1996;69:541-544.
39. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 2003;54:363-375.
40. Mellers JD, Quinn NP, Ron MA. Psychotic and depressive symptoms in Parkinson's disease. A study of the growth hormone response to apomorphine. Br J Psychiatry 1995;167:522-526.
41. Nakano I, Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 1984;15:415-418.
42. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of Parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001;16:1171-1195.
43. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomized controlled study. J Neurol Neurosurg Psychiatry 2002;72:708-712.
44. Leroi I, Brandt J, Reich SG, et al. Randomized placebo controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004;19:1-8.
45. Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord 2001;16:507-510.
46. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Related Disord 2002;8:193-197.